LOTUS PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 314.5 TWD | +0.80% |
|
+0.96% | +15.62% |
| Sales 2024 * | 18.82B 578M | Sales 2025 * | 21.2B 651M | Capitalization | 83.18B 2.55B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.84B 149M | Net income 2025 * | 6.2B 190M | EV / Sales 2024 * | 4.72 x |
| Net Debt 2024 * | 5.71B 175M | Net Debt 2025 * | 1.56B 47.98M | EV / Sales 2025 * | 4 x |
| P/E ratio 2024 * |
17
x | P/E ratio 2025 * |
13.9
x | Employees | 1,099 |
| Yield 2024 * |
1.7% | Yield 2025 * |
2.38% | Free-Float | 48.47% |
More Fundamentals
* Assessed data
More news
Latest transcript on Lotus Pharmaceutical Co., Ltd.
More press releases
More news
| 1 day | +0.80% | ||
| 1 week | +0.96% | ||
| Current month | +3.45% | ||
| 1 month | +7.34% | ||
| 3 months | +14.99% | ||
| 6 months | +33.26% | ||
| Current year | +15.62% |
1 week
309.00
326.00
1 month
301.00347.00
Current year
262.50347.00
1 year
205.00349.50
3 years
65.80349.50
5 years
44.55349.50
10 years
40.50349.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 14-09-28 | |
I ling Tian
DFI | Director of Finance/CFO | - | 16-10-31 |
Ying Ming Yue
COO | Chief Operating Officer | - | 22-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vilhelm Wessman
CHM | Chairman | 54 | 15-04-22 |
| Director/Board Member | 60 | 14-08-10 | |
| Director/Board Member | 61 | 15-04-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 7 M€ | +0.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 314.5 | +0.80% | 3,089,031 |
| 24-04-25 | 312 | -2.65% | 4,600,753 |
| 24-04-24 | 320.5 | 0.00% | 6,155,348 |
| 24-04-23 | 320.5 | +2.40% | 5,703,729 |
| 24-04-22 | 313 | +0.48% | 4,675,028 |
End-of-day quote Taiwan S.E., April 25, 2024
More quotes
Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
314.5
TWD
Average target price
390.2
TWD
Spread / Average Target
+24.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.62% | 2.53B | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.26% | 144B |
- Stock Market
- Equities
- 1795 Stock
